Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial
Publication
, Conference
Swords, RT; Savona, MR; Maris, MB; Erba, HP; Berdeja, JG; Foran, JM; Hua, Z; Faessel, HM; Dash, AB; Sedarati, F; Dezube, BJ; Medeiros, BC
Published in: BLOOD
December 6, 2014
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Swords, R. T., Savona, M. R., Maris, M. B., Erba, H. P., Berdeja, J. G., Foran, J. M., … Medeiros, B. C. (2014). Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial. In BLOOD (Vol. 124). San Francisco, CA: AMER SOC HEMATOLOGY.
Swords, Ronan T., Michael R. Savona, Michael B. Maris, Harry P. Erba, Jesus G. Berdeja, James M. Foran, Zhaowei Hua, et al. “Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial.” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.
Swords RT, Savona MR, Maris MB, Erba HP, Berdeja JG, Foran JM, et al. Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial. In: BLOOD. AMER SOC HEMATOLOGY; 2014.
Swords, Ronan T., et al. “Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial.” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.
Swords RT, Savona MR, Maris MB, Erba HP, Berdeja JG, Foran JM, Hua Z, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Medeiros BC. Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial. BLOOD. AMER SOC HEMATOLOGY; 2014.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology